

Screening Ocular Toxicity of Selected Drugs - Reference List

1. Cheng, H.C., et al., *Amiodarone-Associated Optic Neuropathy: A Nationwide Study*. Ophthalmology, 2015. **122**(12): p. 2553-9.
2. Wang, A.G. and H.C. Cheng, *Amiodarone-Associated Optic Neuropathy: Clinical Review*. Neuroophthalmology, 2017. **41**(2): p. 55-58.
3. Mandal, P., et al., *Fingolimod: therapeutic mechanisms and ocular adverse effects*. Eye (Lond), 2017. **31**(2): p. 232-240.
4. Zarbin, M.A., et al., *Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis*. Ophthalmology, 2013. **120**(7): p. 1432-9.
5. Marmor, M.F., et al., *Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)*. Ophthalmology, 2016. **123**(6): p. 1386-94.
6. Melles, R.B. and M.F. Marmor, *Pericentral retinopathy and racial differences in hydroxychloroquine toxicity*. Ophthalmology, 2015. **122**(1): p. 110-6.
7. Yusuf, I.H., et al., *The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary*. Eye (Lond), 2018.
8. Doshi, R.R., et al., *Pseudocystic foveal cavitation in tamoxifen retinopathy*. Am J Ophthalmol, 2014. **157**(6): p. 1291-1298 e3.
9. Heier, J.S., et al., *Screening for ocular toxicity in asymptomatic patients treated with tamoxifen*. Am J Ophthalmol, 1994. **117**(6): p. 772-5.
10. Fuzzard, D.R., H.G. Mack, and R.C. Symons, *Bilateral retrobulbar optic neuropathy in the setting of interferon alpha-2a therapy*. Case Rep Ophthalmol, 2014. **5**(2): p. 270-6.
11. Sergott, R.C., *Recommendations for visual evaluations of patients treated with vigabatrin*. Curr Opin Ophthalmol, 2010. **21**(6): p. 442-6.
12. Rajjoub, L.Z., N. Chadha, and D.A. Belyea, *Intermittent acute angle closure glaucoma and chronic angle closure following topiramate use with plateau iris configuration*. Clin Ophthalmol, 2014. **8**: p. 1351-4.
13. Richa, S. and J.C. Yazbek, *Ocular adverse effects of common psychotropic agents: a review*. CNS Drugs, 2010. **24**(6): p. 501-26.
14. Libershteyn, Y., *Ethambutol/Linezolid Toxic Optic Neuropathy*. Optom Vis Sci, 2016. **93**(2): p. 211-7.
15. Sharma, P. and R. Sharma, *Toxic optic neuropathy*. Indian J Ophthalmol, 2011. **59**(2): p. 137-41.
16. Beaulieu, R.A., R.E. Warwar, and B.M. Buerk, *Canthaxanthin retinopathy with visual loss: a case report and review*. Case Rep Ophthalmol Med, 2013. **2013**: p. 140901.
17. Di Nicola, M., et al., *Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature*. Biomed Res Int, 2015. **2015**: p. 249617.
18. Wu, C.H., et al., *Deferoxamine retinopathy: spectral domain-optical coherence tomography findings*. BMC Ophthalmol, 2014. **14**: p. 88.
19. Shah, V.A., et al., *Talc retinopathy*. Ophthalmology, 2008. **115**(4): p. 755-755 e2.
20. Fraser-Bell, S. and M. Capon, *Talc retinopathy*. Clin Exp Ophthalmol, 2002. **30**(6): p. 432-3.
21. Labriola, L.T., D. Jeng, and A.A. Fawzi, *Retinal toxicity of systemic medications*. Int Ophthalmol Clin, 2012. **52**(1): p. 149-66.
22. Santaella, R.M. and F.W. Fraunfelder, *Ocular adverse effects associated with systemic medications : recognition and management*. Drugs, 2007. **67**(1): p. 75-93.

23. The Royal College of Ophthalmologists *The Ocular Side-Effects of Vigabatrin (Sabril) Information and Guidance for Screening*. March 2008. <https://www.rcophth.ac.uk/wp-content/uploads/2015/01/2008-SCI-020-The-Ocular-Side-Effects-of-Vigabatrin-Sabril.pdf>
24. Watts, P. *A Review of the Ocular side effects of Topiramate*. Reviewed by Paediatric Ophthalmology Subcommittee, Royal College of Ophthalmologists. https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2010_PROF_122_Review_of_Ocular_side_effects_of_Topiramate-2.pdf
25. Boughton, B. *Watch for Ocular Effects of Breast Cancer Drugs*. American Academy of Ophthalmology EyeNet Magazine, March 2013. <https://www.aao.org/eyenet/article/watch-ocular-effects-of-breast-cancer-drugs>
26. American Optometric Association *Optometric Clinical Practice Recommendations for Monitoring Ocular Toxicity of Selected Medications*. <https://www.aoa.org/documents/optometrists/Ocular-Toxicity.pdf>